Adrenergic alpha-2 Receptor Agonists
"Adrenergic alpha-2 Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS.
| Descriptor ID |
D058647
|
| MeSH Number(s) |
D27.505.519.625.050.100.100.200 D27.505.696.577.050.100.100.200
|
| Concept/Terms |
Adrenergic alpha-2 Receptor Agonists- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha 2 Receptor Agonists
- Adrenergic alpha2-Agonists
- Adrenergic alpha2 Agonists
- alpha2-Agonists, Adrenergic
- Adrenergic alpha-2 Agonists
- Adrenergic alpha 2 Agonists
- Agonists, Adrenergic alpha-2
- alpha-2 Agonists, Adrenergic
- Adrenergic alpha-2 Receptor Agonist
- Adrenergic alpha 2 Receptor Agonist
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic alpha-2 Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic alpha-2 Receptor Agonists".
This graph shows the total number of publications written about "Adrenergic alpha-2 Receptor Agonists" by people in this website by year, and whether "Adrenergic alpha-2 Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic alpha-2 Receptor Agonists" by people in Profiles.
-
Klassen SA, Limberg JK, Harvey RE, Wiggins CC, Spafford JE, Iannarelli NJ, Senefeld JW, Nicholson WT, Curry TB, Joyner MJ, Shoemaker JK, Baker SE. Human sympathetic neuronal discharge and recruitment patterns regulate neuropeptide Y bioavailability. Am J Physiol Heart Circ Physiol. 2024 12 01; 327(6):H1599-H1605.
-
Klassen SA, Limberg JK, Harvey RE, Wiggins CC, Iannarelli NJ, Senefeld JW, Nicholson WT, Curry TB, Joyner MJ, Shoemaker JK, Baker SE. Central a2-adrenergic mechanisms regulate human sympathetic neuronal discharge strategies. J Physiol. 2024 08; 602(16):4053-4071.
-
Bielory L, Schoenberg D. Emerging Therapeutics for Ocular Surface Disease. Curr Allergy Asthma Rep. 2019 02 28; 19(3):16.
-
Wilens TE, McBurnett K, Turnbow J, Rugino T, White C, Youcha S. Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD. J Atten Disord. 2017 01; 21(2):110-119.
-
Cunningham ET, London NJ, Moorthy R, Garg SJ, Zierhut M. Drugs, Inflammation, and the Eye. Ocul Immunol Inflamm. 2016; 24(2):125-7.
-
Martin P, Satin L, Kahn RS, Robinson A, Corcoran M, Purkayastha J, Youcha S, Ermer JC. A thorough QT study of guanfacine. Int J Clin Pharmacol Ther. 2015 Apr; 53(4):301-16.
-
Findling RL, McBurnett K, White C, Youcha S. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014 Jun; 24(5):245-52.
-
Feke GT, Bex PJ, Taylor CP, Rhee DJ, Turalba AV, Chen TC, Wand M, Pasquale LR. Effect of brimonidine on retinal vascular autoregulation and short-term visual function in normal tension glaucoma. Am J Ophthalmol. 2014 Jul; 158(1):105-112.e1.
-
Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, Rubin J. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry. 2013 Sep; 52(9):921-30.
-
Peterson JD, Bilyk JR, Sergott RC. But it's not all there. Surv Ophthalmol. 2013 Sep-Oct; 58(5):492-9.